COPD clinical trials, in English

This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.

NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of side effects. Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase.

NCT03799354 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion.

NCT05061368 · Official ClinicalTrials.gov record · University of Alberta

The aim of this study is to determine whether an intervention with frequent thermotherapy will be able to reduce the amount of colonizing bacteria in the bronchoalveolar lavage sample and eradicate the colonizing bacteria.

NCT05351242 · Official ClinicalTrials.gov record · Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Pulmonary rehabilitation (PR) is an effective intervention for reducing hospital readmissions, secondary events, and mortality in patients with respiratory pathologies. The program should not be improved by introducing new subjects such as circadian rhythm.

NCT06366113 · Official ClinicalTrials.gov record · Michaël RACODON

Recovery after lung transplantation (LTx) may be complicated by prolonged mechanical ventilation (MV) and protracted intensive care unit (ICU) stay leading to immobilization and impaired health-related quality of life (HRQoL). In the critical care setting, diaphragm atrophy and weakness have been associated with difficulty weaning from MV, increased risk for readmission to hospital or ICU, and increased mortality.

NCT06370832 · Official ClinicalTrials.gov record · University Health Network, Toronto

Chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD), are a leading cause of death globally. These diseases not only contribute significantly to mortality but also lead to a decline in physical capacity, limiting daily activities and perpetuating a vicious cycle of deconditioning.

NCT06811402 · Official ClinicalTrials.gov record · Fondation Hôpital Saint-Joseph

A Multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, Parallel Group, Phase 3 Study to measure the how well it works and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT06878261 · Official ClinicalTrials.gov record · AstraZeneca

A Multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, Parallel Group, Phase 3 Study to measure the how well it works and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT06883305 · Official ClinicalTrials.gov record · AstraZeneca

The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. this study wants to confirm the safety and how well it works of the Nuvaira Lung Denervation System in the treatment of COPD.

NCT07051707 · Official ClinicalTrials.gov record · Nuvaira, Inc.

LPS18583 is a multinational, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group, Phase 4 study with 2 treatment groups. this study wants to assess the effect of dupilumab compared with dummy treatment (placebo) on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive).

NCT07053423 · Official ClinicalTrials.gov record · Sanofi

Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.

NCT07069829 · Official ClinicalTrials.gov record · AstraZeneca

The OBS19236 is a retrospective and prospective, non-treatment watch-and-measure (no experimental treatment required) study in COPD patients treated with dupilumab as part of routine clinical care. It will follow-up about 350 to 500 participants over 36 months in up to 50 sites in France.

NCT07380711 · Official ClinicalTrials.gov record · Sanofi

Introduction: Pulmonary rehabilitation programs (PRPs) are known to reduce symptoms such as dyspnea and fatigue, while improving functional capacity and quality of life in individuals with chronic obstructive pulmonary disease (COPD). However, the benefits of an initial pulmonary rehabilitation program (PRP) tend to diminish rapidly over time, prompting the development of strategies to maintain these effects.

NCT07394712 · Official ClinicalTrials.gov record · Institut de Recerca Biomèdica de Lleida

This research will be conducted using a pre-test and post-test control group experimental design to measure the effect of telenursing intervention on oral health in individuals with COPD.

NCT07462221 · Official ClinicalTrials.gov record · Çanakkale Onsekiz Mart University

The purpose of this clinical trial is to determine the best initial non-invasive respiratory support (NIRS) strategy for adults who present to the emergency department with acute hypoxemic respiratory failure, a condition in which blood oxygen levels are dangerously low and require urgent treatment. This study compares two commonly used non-invasive respiratory support strategies to evaluate their effectiveness and safety, based on important patient outcomes during hospitalization, including survival, the need for invasive mechanical ventilation, and the duration of respiratory support.

NCT07558265 · Official ClinicalTrials.gov record · Ohio State University

Helicobacter pylori (HP) is a well-established pathogen responsible for chronic gastritis and peptic ulcer disease. Its presence has been implicated in the development of gastric malignancies such as adenocarcinoma and mucosa-associated lymphoid tissue lymphoma.

NCT07574879 · Official ClinicalTrials.gov record · Zagazig University

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days).

NCT07587658 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The STRIDE Registry will measure the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.

NCT07612878 · Official ClinicalTrials.gov record · Sanofi

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

NCT07705737 · Official ClinicalTrials.gov record · Connect Biopharm LLC

The purpose of the study is to investigate the how well it works of galvokimig versus dummy treatment (placebo) in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

NCT07725939 · Official ClinicalTrials.gov record · UCB Biopharma SRL

This feasibility cluster-controlled randomly assigned trial (RCT) evaluates a complex intervention for the delivery of primary palliative care in Family Health Units (FHUs). The intervention consists of training General Practitioners (GPs) in palliative care through a 30 hour e-learning program and implementing a structured consultation model (4 consultations over 12 weeks) for adult patients with advanced chronic illness.

NCT07737899 · Official ClinicalTrials.gov record · University of Coimbra

The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with dummy treatment (placebo). The study will last approximately one year.

NCT07759245 · Official ClinicalTrials.gov record · Eli Lilly and Company

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to dummy treatment (placebo) in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

NCT07780656 · Official ClinicalTrials.gov record · GlaxoSmithKline

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to dummy treatment (placebo) in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

NCT07780669 · Official ClinicalTrials.gov record · GlaxoSmithKline

This prospective, real-world watch-and-measure (no experimental treatment required) study (T2AIR Study) evaluates the long-term how well it works and safety of six biologics targeting Type 2 inflammation - omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab - in patients with chronic airway diseases, including asthma and COPD under routine clinical practice in China. The primary objective is to determine the annualized exacerbation rate (AER) over 12 months of treatment.

NCT07823842 · Official ClinicalTrials.gov record · Shanghai Pulmonary Hospital, Shanghai, China

This study wants to measure the how well it works and safety of ensifentrine (MK-5884) compared with dummy treatment (placebo) for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also measure the how well it works of ensifentrine compared with dummy treatment (placebo) in improving lung function, improving health related quality of life, and preventing severe exacerbations.

NCT07874815 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are: * Does targeted NMES improve diaphragm thickening fraction and excursion as measured by diaphragm ultrasound?

NCT07910006 · Official ClinicalTrials.gov record · Universitas Padjadjaran

This is a multicenter, watch-and-measure (no experimental treatment required) study aiming to construct and validate an Impulse Oscillometry (IOS)-based platform for the screening, diagnosis, and management of chronic airway diseases (COPD and asthma). Phase 1 is a cross-sectional study to build and validate diagnostic models for COPD and asthma using IOS parameters, with respiratory specialists' clinical diagnosis as the gold standard.

NCT07910409 · Official ClinicalTrials.gov record · Beijing Chao Yang Hospital

This study is designed for adults who have, or suspected to have, a long-term respiratory (lung) condition such as Alpha-1 Antitrypsin Deficiency (AATD), chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, or interstitial lung disease (ILD). The aim of the study is to help participants become familiar with the clinical trials unit environment and research team before deciding whether they would like to take part in future clinical trials.

NCT07924462 · Official ClinicalTrials.gov record · Richmond Research Institute